WO2012092594A3 - Preparations for topical prevention and/or treatment of oral allergic symptoms due to oral contact with fruits and/or vegetables - Google Patents

Preparations for topical prevention and/or treatment of oral allergic symptoms due to oral contact with fruits and/or vegetables Download PDF

Info

Publication number
WO2012092594A3
WO2012092594A3 PCT/US2011/068185 US2011068185W WO2012092594A3 WO 2012092594 A3 WO2012092594 A3 WO 2012092594A3 US 2011068185 W US2011068185 W US 2011068185W WO 2012092594 A3 WO2012092594 A3 WO 2012092594A3
Authority
WO
WIPO (PCT)
Prior art keywords
oral
treatment
fruits
vegetables
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/068185
Other languages
French (fr)
Other versions
WO2012092594A2 (en
Inventor
Ziv HARISH, M.D.
Ehud Arbit
Isaac Rubinstein
Russ Weinzimmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2013547705A priority Critical patent/JP5996553B2/en
Priority to EP11854273.7A priority patent/EP2658538A2/en
Publication of WO2012092594A2 publication Critical patent/WO2012092594A2/en
Publication of WO2012092594A3 publication Critical patent/WO2012092594A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A topical preparation of at least one of a mast cell stabilizer and an antihistamine is disclosed for prevention and/or treatment of oral allergy syndrome, or other allergy-related oral inflammatory processes. For example, the topical administration of Cromolyn Sodium prior to ingestion of raw fruits and raw vegetables may be used to prevent oral allergy symptoms. The topical administration can be performed by use of a solution, a powder, an aerosol, a tablet, a chewable tablet, a gel, a melting strip, a mouth rinse, a mouth swab, or a piece of candy, and may be combined with carrier molecules and/or mucoadhesive molecules to enhance efficacy.
PCT/US2011/068185 2010-12-30 2011-12-30 Preparations for topical prevention and/or treatment of oral allergic symptoms due to oral contact with fruits and/or vegetables Ceased WO2012092594A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2013547705A JP5996553B2 (en) 2010-12-30 2011-12-30 Preparation for prevention and / or treatment by surface application of oral allergy symptoms resulting from oral contact with fruits and / or vegetables
EP11854273.7A EP2658538A2 (en) 2010-12-30 2011-12-30 Preparations for topical prevention and/or treatment of oral allergic symptoms due to oral contact with fruits and/or vegetables

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98172610A 2010-12-30 2010-12-30
US12/981,726 2010-12-30

Publications (2)

Publication Number Publication Date
WO2012092594A2 WO2012092594A2 (en) 2012-07-05
WO2012092594A3 true WO2012092594A3 (en) 2012-10-26

Family

ID=46383882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/068185 Ceased WO2012092594A2 (en) 2010-12-30 2011-12-30 Preparations for topical prevention and/or treatment of oral allergic symptoms due to oral contact with fruits and/or vegetables

Country Status (4)

Country Link
US (1) US20130017247A1 (en)
EP (1) EP2658538A2 (en)
JP (1) JP5996553B2 (en)
WO (1) WO2012092594A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2705244T3 (en) 2010-06-16 2019-03-22 Inflammatory Response Res Inc Levocetirizine and montelukast for the treatment of influenza and the common cold
US20140370086A1 (en) * 2010-12-30 2014-12-18 Ziv Harish Sublingual immunotherapy with reduced oral itchiness
RU2705097C2 (en) * 2013-03-13 2019-11-05 Ирр, Инк. Using levocetirizine and montelukast in treating anaphylaxis
ES2660494T3 (en) 2013-03-13 2018-03-22 14779507 Use of levocetirizine and montelukast in the treatment of a traumatic injury
CN105228700A (en) 2013-03-13 2016-01-06 炎症反应研究公司 Levocetirizine and the purposes of montelukast in treatment autoimmune disease
EP2968309A4 (en) 2013-03-13 2016-08-31 Inflammatory Response Res Inc Use of levocetirizine and montelukast in the treatment of vasculitis
CN104546731A (en) * 2013-10-09 2015-04-29 重庆安格龙翔医药科技有限公司 Epinastine hydrochloride granules and preparation method thereof
JP2016535793A (en) * 2013-11-11 2016-11-17 ジヴ エム．ディー． ハリシュ Formulations and methods for prevention and treatment of oral allergy syndrome
WO2015080292A1 (en) * 2013-11-29 2015-06-04 旭化成イーマテリアルズ株式会社 Polymer electrolyte film
JP2017505348A (en) * 2014-02-10 2017-02-16 パタラ ファーマ リミテッド ライアビリティ カンパニー Mast cell stabilizer for the treatment of lung diseases
PL3104853T3 (en) 2014-02-10 2020-05-18 Respivant Sciences Gmbh TREATMENT OF SYSTEMIC DISORDERS WITH TORSION CELL STABILIZERS
JP2017526728A (en) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド Levocetirizine and montelukast in the treatment of inflammation-mediated conditions
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017027387A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
JP2019528320A (en) 2016-08-31 2019-10-10 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ Cromolyn composition for the treatment of chronic cough due to idiopathic pulmonary fibrosis
EP3522983A4 (en) 2016-10-07 2020-06-03 Respivant Sciences GmbH CROMOLYNE-BASED COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS
CN119970625A (en) * 2018-01-15 2025-05-13 西雅图咖米公司 Semisolid antihistamine composition and preparation and use method thereof
CN110567949B (en) * 2019-09-10 2021-12-14 广东天地和实业控股集团有限公司 Bacterial toxin detection method and treatment instrument applied to same
WO2021236518A1 (en) 2020-05-19 2021-11-25 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090297563A1 (en) * 2004-10-27 2009-12-03 Anders Borglum Diagnosis And Treatment of Immune-Related Diseases
US20100166804A1 (en) * 2007-05-23 2010-07-01 Dennis Penn Methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1997478T3 (en) * 2001-02-15 2013-12-09 Access Pharma Inc Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090297563A1 (en) * 2004-10-27 2009-12-03 Anders Borglum Diagnosis And Treatment of Immune-Related Diseases
US20100166804A1 (en) * 2007-05-23 2010-07-01 Dennis Penn Methods

Also Published As

Publication number Publication date
US20130017247A1 (en) 2013-01-17
WO2012092594A2 (en) 2012-07-05
JP5996553B2 (en) 2016-09-21
EP2658538A2 (en) 2013-11-06
JP2014501287A (en) 2014-01-20

Similar Documents

Publication Publication Date Title
NZ602557A (en) Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
PH12013501143A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
WO2013066839A3 (en) Compounds and methods
WO2013066835A3 (en) Compounds and methods
BR112013016606A2 (en) processes for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
WO2013006795A3 (en) Antiviral compositions and methods of their use
MX339470B (en) Nicotine containing formulation.
WO2012048846A3 (en) Phosphate binder formulation for simple ingestion
WO2013116798A3 (en) A method for the treatment and/or prevention of oral allergic symptoms of the lips due to oral contact with a food allergen
WO2013022243A3 (en) Novel biphenyl derivative or a pharmaceutically acceptable salt thereof, and pharmaceutical composition for preventing or treating inflammatory diseases or autoimmune diseases comprising same as an active ingredient
WO2012093234A3 (en) Sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycans for treating diseases caused by the influenza virus
TN2015000267A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
UA112767C2 (en) PHARMACEUTICAL PREPARATION CONTAINING SELENITE OR SELF-CONTAINING COMPOUNDS FOR TREATMENT OF DISPLASIONS OR CANCER CANCER
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
WO2011139252A3 (en) Efervescent formulations comprising cefdinir
WO2009084020A3 (en) Topical composition comprising halobetasol and salicylic acid
WO2010054495A3 (en) Non-aqueous colloidal formulation
WO2012030308A3 (en) Formulation comprising cellobiose
WO2008105533A1 (en) Adiponectin secretion-stimulating agent comprising capsinoid compound
WO2013043011A3 (en) Pharmaceutical composition containing puerariae flos extracts as active ingredients for preventing and treating endometriosis
WO2012111934A3 (en) Pharmaceutical composition for preventing and treating inflammatory disease or asthma containing an extract of decaspermum fruticosum
WO2012128496A3 (en) Pharmaceutical composition for preventing or treating asthma containing maackiain as an active ingredient
WO2012060791A3 (en) Production method for pharmaceutical compositions comprising cefdinir
WO2011159254A3 (en) The use of des-aspartate-angiotensin i in inflammation-related pathologies and diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11854273

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013547705

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011854273

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011854273

Country of ref document: EP